Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference

BOSTON, MA / ACCESSWIRE / May 21, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology

Related Keywords

Washington ,District Of Columbia ,United States ,Ukraine ,Boston ,Massachusetts ,American ,Joe Patneaude ,Gewinn Nur ,Pieris Pharmaceuticals ,American Thoracic Society ,Pieris Pharmaceuticals Inc ,Company Quarterly Reports On Form ,Nasdaq ,Pieris Pharmaceuticals Inc View ,International Conference ,Securities Exchange ,Exchange Commission ,Chief Development Officer ,Securities Act ,Securities Exchange Act ,Annual Report ,Quarterly Reports ,Relations Contact ,Inc View ,Pieris ,Pharmaceuticals ,Nnounces ,Presentation ,Romising ,Reclinical ,Data ,023 ,Nternational ,Conference ,